Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Ajanta Pharma Sets Up Wholly Owned Subsidiary in Ireland

Ajanta Pharma looks to expand ops in high-growth Asian, African geographies

Ruchika Sharma3 July 2023 1:30 PM IST

"We plan to ramp up our presence in these markets and add value to the patients' choices through our differentiated product portfolio," the drug firm...

Solara Active Pharma Sciences Mangalore facility successfully completes USFDA inspection

Granules India completes USFDA audit at Visakhapatnam facility with zero 483 observations

Ruchika Sharma3 July 2023 12:30 PM IST

Hyderabad: Granules India Limited, a vertically integrated pharmaceutical company, has completed the U.S. Food and Drug Administration’s (US FDA)...

Zydus Lifesciences gets EIR from USFDA for Pharmez facility

Ruchika Sharma3 July 2023 11:44 AM IST

Ahmedabad: Zydus Lifesciences has recently announced thatthe Company has received the Establishment Inspection Report (EIR) from the United States...

Eli Lilly joins trillion-dollar club, fueled by weight loss drug demand boom

Eli Lilly to buy Sigilon Therapeutics

Ruchika Sharma2 July 2023 1:00 PM IST

Indianapolis: Eli Lilly and Companyand Sigilon Therapeutics, Inc. have announced a definitive agreement for Lilly to acquire Sigilon, a...

Bayer announces positive results from phase I trial of Bemdaneprocel to treat Parkinson's disease

Ruchika Sharma2 July 2023 11:30 AM IST

Bemdaneprocel, an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into...

Sanofi to buy Vigil Neuroscience in USD 470 million deal

Translumina acquires Blue Medical Devices, Netherlands

Ruchika Sharma2 July 2023 10:00 AM IST

The acquisition shall also enable Translumina to use the patented Drug application technology of Blue Medical in other product lines in peripheral and...

Fire broke out in solvent reactor at Sahithi Pharma unit, 6 injured

Ruchika Sharma30 Jun 2023 3:08 PM IST

Hyderabad: At least six people have been injured in a fire at a unit of a privately held pharmaceutical company in the southern Indian state of...

Lupin secures SBTi validation for emission reduction targets

Lupin receives over Rs 205 crore from AbbVie for meeting key product development milestone

Ruchika Sharma30 Jun 2023 2:00 PM IST

Mumbai: Global pharma major Lupin Limited has announced the achievement of a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue ...

USFDA Grants Orphan Drug Status to Shilpa-mAbTree Biologic for Rare Blood Cancers

Shilpa Biologicals gets marketing authorization permission for Adalimumab 40 mg/0.4mL injection in prefilled syringe in India

Ruchika Sharma30 Jun 2023 12:30 PM IST

Karnataka: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), has received the Marketing...

US FDA declines to approve Regeneron's higher dose Eylea

Ruchika Sharma30 Jun 2023 11:00 AM IST

Regeneron was seeking approval for the drug to treat wet AMD, the leading cause of blindness among the elderly, and two eye diseases that are common...

Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell Carcinoma

Merck, Ridgeback Biotherapeutics withdraw COVID pill Molnupiravir application in EU

Ruchika Sharma30 Jun 2023 10:00 AM IST

Merck and Co and partner Ridgeback Biotherapeutics said on Tuesday they had withdrawn their COVID-19 pill application in the European Union,...

Granules India inaugurates two advanced Centres of Excellence at IIT Hyderabad

Granules India warns of significant loss of revenue, profitability due to cyber attack

Ruchika Sharma29 Jun 2023 3:38 PM IST

The company said on June 29 that a ransomware group had claimed responsibility for the incident.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok